Federal Appeals Court Upholds Martin Shkreli's Lifetime Ban from Pharmaceutical Industry

The decision comes after Shkreli's notorious price hike of life-saving drug Daraprim and subsequent conviction for defrauding investors.

Martin Shkreli, known as 'Pharma Bro', is unable to return to the pharmaceutical industry after a federal appeals court upheld his lifetime ban.
The case was brought by the Federal Trade Commission and several states, citing Shkreli's antitrust violations.
Shkreli gained notoriety in 2015 when he raised the price of the life-saving drug Daraprim by over 4,000% overnight.
He served more than four years in prison for defrauding investors in two hedge funds and another drugmaker.
Since his release from prison in May 2022, Shkreli has been working as a software developer and a consultant for a law office.